Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
When surveyed about their outlook, pharma industry leaders said they felt plagued by uncertainty and beaten down by budget cuts. More than half worried they would receive pink slips by the end of this year. But some more optimistic execs predicted new investment in their departments, and many figured staffing levels will endure, at least for this year.
Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.
Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.
The U.S. Department of Justice closed out its probe of a key Brilinta trial--and without further ado. No additional label warnings. And certainly no forced withdrawal from the U.S. market.
Biogen Idec has added another bow to its multiple sclerosis quiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of the MS market.
The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.
Why do cancer drugs cost so much? We all know the stock answer--because companies need to recoup their development costs. Whether we believe it is something else, as Peter Bach of the Center for Health Policy and Outcomes writes in Forbes.
Almost half of doctors bar their doors to pharma sales reps some way, somehow. What with all the talk about rep access to physicians, that state of things may seem quote-unquote normal. But it's not. Just 6 years ago, the numbers were quite different.
It started in 2011 with just a handful of drugs. CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. Now, CVS' excluded list comprises almost 100 drugs and related products.